Medtronic (MDT) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Medtronic (NYSE: MDT) in the last few weeks:

• 2/21/2026 – Medtronic was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/18/2026 – Medtronic had its “overweight” rating reaffirmed by Barclays PLC. They now have a $118.00 price target on the stock.
• 2/18/2026 – Medtronic had its price target lowered by Truist Financial Corporation from $107.00 to $103.00. They now have a “hold” rating on the stock.
• 2/18/2026 – Medtronic was upgraded by Mizuho to “strong-buy”.
• 2/18/2026 – Medtronic had its price target lowered by JPMorgan Chase & Co. from $105.00 to $100.00. They now have a “neutral” rating on the stock.
• 2/18/2026 – Medtronic had its price target lowered by Leerink Partners from $120.00 to $119.00. They now have an “outperform” rating on the stock.
• 2/18/2026 – Medtronic had its price target lowered by Robert W. Baird from $103.00 to $100.00. They now have a “neutral” rating on the stock.
• 2/17/2026 – Medtronic had its price target lowered by Needham & Company LLC from $121.00 to $120.00. They now have a “buy” rating on the stock.
• 2/13/2026 – Medtronic is now covered by Barclays PLC. They set an “overweight” rating and a $116.00 price target on the stock.
• 2/9/2026 – Medtronic was upgraded by Needham & Company LLC from “hold” to “buy”. They now have a $121.00 price target on the stock.
• 2/4/2026 – Medtronic had its “neutral” rating reaffirmed by UBS Group AG. They now have a $104.00 price target on the stock.
• 2/3/2026 – Medtronic is now covered by Citigroup Inc.. They set a “buy” rating and a $117.00 price target on the stock.
• 1/30/2026 – Medtronic is now covered by CICC Research. They set an “outperform” rating on the stock.
• 1/30/2026 – Medtronic is now covered by Wells Fargo & Company. They set an “overweight” rating and a $114.00 price target on the stock.
• 1/23/2026 – Medtronic was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/9/2026 – Medtronic had its price target raised by Sanford C. Bernstein from $111.00 to $112.00. They now have an “outperform” rating on the stock.
• 1/8/2026 – Medtronic had its price target raised by Barclays PLC from $111.00 to $116.00. They now have an “overweight” rating on the stock.
• 1/6/2026 – Medtronic was upgraded by William Blair from “market perform” to “outperform”.
• 1/5/2026 – Medtronic had its “neutral” rating reaffirmed by Piper Sandler.
• 1/3/2026 – Medtronic was downgraded by Wall Street Zen from “buy” to “hold”.
• 12/29/2025 – Medtronic had its “buy (b-)” rating reaffirmed by Weiss Ratings.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).